TY - JOUR
T1 - Clinical utility of dabigatran in United Arab Emirates
T2 - A pharmacovigilance study
AU - Shehab, Abdulla
AU - Elnour, Asim A.
AU - Sadik, Adel
AU - Abu Mandil, Mahmoud
AU - AlShamsi, Ali
AU - Al Suwaidi, Aesha
AU - Bhagavathula, Akshayasrikanth
AU - Erkekoglu, Pinar
AU - Hamad, Farah
AU - Al Nuaimi, Saif K.
N1 - Publisher Copyright:
© 2015, Saudi Arabian Armed Forces Hospital. All rights reserved.
PY - 2015/11
Y1 - 2015/11
N2 - Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional study. We retrieved a total of 76 patients who were using dabigatran from September to December 2014 in the Cardiology Clinic at Al-Ain Hospital, Al-Ain, UAE. The primary analysis was designed to test the frequency of bleeding events (rate) with dabigatran 75, 110, and 150 mg. Results: The mean age ± standard deviation of cohort was 67.9 ± 1.5 years (range; 29-98 years), composed of males (52.6%) with mean age of 66.3 ± 1.7 years, and females (47.4%) with mean age of 69.6 ± 1.1 years. The highest age group was those between 61-80 years (60.5%). Most comprised the age strata of ≤75 years (73.7%). The main indication for dabigatran use was atrial fibrillation. The rate of bleeding with dabigatran was 18/76 (23.7%), and melena was the leading cause of bleeding 8/76 (10.7%). The hospitalization rate was 67.1%, dabigatran withdrawal rate was 0.01%, and mortality rate was 6.5%. The cohort had exhibited incidences of minor bleeding with one fatal major bleeding, high co-morbidities, admission, and readmission, which was not directly linked to dabigatran. We did not identify any relation of death due to dabigatran. Conclusion: Dabigatran is a suitable alternative to warfarin obviating the need for repetitive international normalized ratio monitoring, however, it may need plasma drug monitoring.
AB - Objectives: To provide early data regarding clinical utility of dabigatran in Al-Ain, United Arab Emirates (UAE). Methods: This was an ethics approved retrospective cross sectional study. We retrieved a total of 76 patients who were using dabigatran from September to December 2014 in the Cardiology Clinic at Al-Ain Hospital, Al-Ain, UAE. The primary analysis was designed to test the frequency of bleeding events (rate) with dabigatran 75, 110, and 150 mg. Results: The mean age ± standard deviation of cohort was 67.9 ± 1.5 years (range; 29-98 years), composed of males (52.6%) with mean age of 66.3 ± 1.7 years, and females (47.4%) with mean age of 69.6 ± 1.1 years. The highest age group was those between 61-80 years (60.5%). Most comprised the age strata of ≤75 years (73.7%). The main indication for dabigatran use was atrial fibrillation. The rate of bleeding with dabigatran was 18/76 (23.7%), and melena was the leading cause of bleeding 8/76 (10.7%). The hospitalization rate was 67.1%, dabigatran withdrawal rate was 0.01%, and mortality rate was 6.5%. The cohort had exhibited incidences of minor bleeding with one fatal major bleeding, high co-morbidities, admission, and readmission, which was not directly linked to dabigatran. We did not identify any relation of death due to dabigatran. Conclusion: Dabigatran is a suitable alternative to warfarin obviating the need for repetitive international normalized ratio monitoring, however, it may need plasma drug monitoring.
UR - http://www.scopus.com/inward/record.url?scp=84949803317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949803317&partnerID=8YFLogxK
U2 - 10.15537/smj.2015.11.12154
DO - 10.15537/smj.2015.11.12154
M3 - Article
C2 - 26593161
AN - SCOPUS:84949803317
SN - 0379-5284
VL - 36
SP - 1290
EP - 1298
JO - Saudi Medical Journal
JF - Saudi Medical Journal
IS - 11
ER -